Study of FT2109 for psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests an experimental drug called FT2109 for people with psoriatic arthritis, a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if FT2109 can reduce symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your body mass index (BMI) must be between 18 and 40.
- You need to have had psoriatic arthritis for at least 6 months, with active joint swelling and pain (at least 3 tender and 3 swollen joints).
- You must have active psoriasis (at least one patch of 2 cm or larger) or nail psoriasis.
- If you've tried biologic or targeted oral treatments, you can have had at most one biologic (but not anti-TNF or anti-IL-17) and one targeted oral (but not JAK inhibitors). If you've never used these, you must have failed at least one or two traditional DMARDs or Apremilast.
- You cannot have other inflammatory conditions (like rheumatoid arthritis, ankylosing spondylitis, lupus, or inflammatory bowel disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, LPX-TI641, to see if it is safe and how it works in the body for people with rheumatoid arthritis or psoriatic arthritis. It may be an option if you have active joint swelling and pain despite standard treatments.
This trial tests an investigational drug (DDY391) in people with moderate to severe psoriatic arthritis. The goal is to see how well it works and if it is safe, which might help reduce joint pain and skin symptoms.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
This study tests an experimental drug called JNJ-88545223 to see if it can reduce joint pain, swelling, and skin plaques in people with active psoriatic arthritis. It may help if you have both joint symptoms and psoriasis.
This study tests an oral investigational pill (CBP-0276) called an oral therapy for psoriatic arthritis. The goal is to see if it reduces joint pain, swelling, and psoriasis symptoms better than a placebo (inactive pill).
This study compares two “treat-to-target” strategies for psoriatic arthritis. One strategy uses imaging to guide treatment changes, and the other uses standard clinic assessments, to see which approach controls symptoms more effectively.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.